Basic Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jun 15, 2022; 13(6): 434-441
Published online Jun 15, 2022. doi: 10.4239/wjd.v13.i6.434
Investigating the specificity of endothelin-traps as a potential therapeutic tool for endothelin-1 related disorders
Arjun Jain, Kristof Bozovicar, Vidhi Mehrotra, Tomaz Bratkovic, Martin H Johnson, Ira Jha
Arjun Jain, Vidhi Mehrotra, Ira Jha, ET-Traps Limited, Cambridge CB3 0JE, United Kingdom
Arjun Jain, Martin H Johnson, Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge CB2 3DY, United Kingdom
Arjun Jain, Vidhi Mehrotra, Accelerate Cambridge, Judge Business School, University of Cambridge, Cambridge CB2 1AG, United Kingdom
Kristof Bozovicar, Tomaz Bratkovic, Department of Pharmaceutical Biology, Faculty of Pharmacy, University of Ljubljana, Slovenia 1000, Slovenia
Author contributions: Jain A and Bozovičar K contributed equally to this work; Jain A, Bozovičar K, Mehrotra V, Bratkovič T performed the experimental analyses and contributed towards writing the article and Johnson M and Jha I revised it critically for important intellectual content.
Institutional review board statement: This study was approved by ET-traps Limited.
Conflict-of-interest statement: The authors have no conflict of interest.
Data sharing statement: Data available from corresponding author, Dr. Arjun Jain at arjun@et-traps.co.uk.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Arjun Jain, MPhil, PhD, Research Scientist, ET-Traps Limited, 28 St Stephens Place, Cambridge CB3 0JE, United Kingdom. jain_arjun@yahoo.com
Received: January 27, 2022
Peer-review started: January 27, 2022
First decision: April 18, 2022
Revised: April 24, 2022
Accepted: May 28, 2022
Article in press: May 28, 2022
Published online: June 15, 2022
Processing time: 131 Days and 5.6 Hours
Core Tip

Core Tip: This study verified the specificity of endothelin (ET)-traps, which are an Fc-based fusion protein that acts as a potential therapeutic for various cET-1 related disorders, including diabetes and chronic kidney disease. ET-traps, unlike ET receptor antagonists, do not completely block the ET system and hence have minimal side effects. ET-traps would help save millions of lives around the world.